Having secured one of last year’s largest funding rounds, AI-focused Formation Bio is now eyeing up 545 million euros ($626 ...

Sanofi and Regeneron’s Dupixent (dupilumab) has been approved by the US Food and Drug Administration (FDA) to treat bullous ...

Formation Bio’s subsidiary, Libertas Bio, has licensed gusacitinib, an oral dual JAK/SYK inhibitor, to Sanofi.

Formation Bio, an AI-native pharma company focused on accelerating drug development, today announced that its subsidiary Libertas Bio has licensed gusacitinib, an oral dual JAK/SYK inhibitor, to ...

RSV is the most common cause of hospitalization in babies, but Sanofi is one of a few companies producing a shot that can ...

Paris: Sanofi has announced that the European Medicines Agency's Committee for Medicinal Products for Human Use (CHMP) has ...

The American Society for Transplantation and Cellular Therapy is proud to announce the release of a refreshed Practice ...

BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) is among the 11 Best Genomics Stocks to Buy According to Hedge Funds. Gena Wang of ...

CHICAGO -- A once-weekly basal insulin had similar safety and efficacy to a daily insulin option, a series of trials from the ...

The third phase of the Vietnam-Denmark Health Partnership Programme kicked off on June 23 as Deputy Minister of Health, Dr.

The US Food and Drug Administration (FDA) has approved dupilumab (Dupixent) as the first targeted therapy for bullous ...

Sarclisa is currently approved in three indications in the EU, across different lines of therapy in adult patients with relapsed and/or refractory (R/R) MM and with NDMM who are not eligible for ...